BioOrbit is a UK space-biotech company that makes pharmaceuticals in microgravity. It uses low Earth orbit to grow highly ordered crystals of biological drugs, a result that is hard to achieve on Earth. The aim is to turn drugs that patients receive by intravenous infusion into subcutaneous forms they can inject themselves.

A NEW KIND OF CDMO

About 70% of the highest-grossing drugs are given intravenously, which keeps treatments such as cancer care inside hospitals. BioOrbit's protein crystallisation work targets that problem. Its core hardware is BOX, an autonomous, modular manufacturing unit about the size of a microwave, designed to operate in microgravity. The company points to a potential 90% cut in hospital drug costs through self-administration and to an antibody market it sizes at $1 trillion.

THE INVESTMENT

Auxxo Female Catalyst Fund invested €0.89 million at Seed in 2026. That is its only cheque so far. The round was co-led by LocalGlobe and Breega, with Seedcamp, Type One, Odin, New Abundance, Robin Cap, 7percent and angel investors. BioOrbit has raised €9.14 million to date. The fund carries the position at a €28.95 million latest-round valuation, a 1.0x multiple.

FOUNDERS AND TEAM

Dr Katie King is founder and CEO. Dr Leonor Teles, an oncology researcher, is co-founder. The team has added deep industry experience: Dr Ken Savin, Chief Science Officer, spent about two decades at Eli Lilly and later served as CSO at Redwire. Dr Molly Mulligan, President of BioOrbit Inc., signed the first in-orbit pharmaceutical royalty agreement.

‍